Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1385&sort=award_id
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=award_id", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=award_id", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1386&sort=award_id", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=award_id" }, "data": [ { "type": "Grant", "id": "9491", "attributes": { "award_id": "75N93019C00051-P00001-9999-2", "title": "CIVICS)PROGRAM - SARS-CoV-2 STUDIES", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-10", "end_date": "2022-03-31", "award_amount": 7342586, "principal_investigator": { "id": 25201, "first_name": "FLORIAN", "last_name": "KRAMMER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "This contract supports the design and evaluation of innovative vaccine candidates and delivery platforms that aim to achieve durable, robust and broadly protective immunity. Activities may include immunologic analyses to inform vaccine design and identify surrogates/correlates of protection; in vitro and in vivo immunogenicity and efficacy testing; assay and reagent development; and clinical studies and trials. Additional studies are being conducted to evaluate the immune response to SARS-CoV-2 infection.", "keywords": [ "2019-nCoV", "Basic Science", "Biological Assay", "COVID-19", "Clinical Research", "Clinical Trials", "Development", "Evaluation", "Immune response", "Immunity", "Immunologics", "In Vitro", "Infection", "Reagent", "Support Contracts", "Vaccine Design", "design", "efficacy testing", "immunogenicity", "in vivo", "innovation", "programs", "vaccine candidate", "vaccine delivery" ], "approved": true } }, { "type": "Grant", "id": "9492", "attributes": { "award_id": "75N93019C00051-P00008-9999-2", "title": "CIVICS PROGRAM - SARS-CoV-2 STUDIES", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-10", "end_date": "2025-08-04", "award_amount": 457311, "principal_investigator": { "id": 25201, "first_name": "FLORIAN", "last_name": "KRAMMER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "This contract supports the design and evaluation of innovative vaccine candidates and delivery platforms that aim to achieve durable, robust and broadly protective immunity. Activities may include immunologic analyses to inform vaccine design and identify surrogates/correlates of protection; in vitro and in vivo immunogenicity and efficacy testing; assay and reagent development; and clinical studies and trials. Additional studies are being conducted to evaluate the immune response to SARS-CoV-2 infection.", "keywords": [ "2019-nCoV", "Biological Assay", "COVID-19", "Clinical Research", "Clinical Trials", "Development", "Evaluation", "Immune response", "Immunity", "Immunologics", "In Vitro", "Reagent", "SARS-CoV-2 infection", "Support Contracts", "Therapeutic Human Experimentation", "Vaccine Design", "design", "efficacy testing", "immunogenicity", "in vivo", "innovation", "programs", "vaccine candidate", "vaccine delivery" ], "approved": true } }, { "type": "Grant", "id": "9490", "attributes": { "award_id": "75N93019C00051-P00008-9999-4", "title": "CIVICS PROGRAM - SARS-CoV-2 STUDIES", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-10", "end_date": "2025-08-04", "award_amount": 1198308, "principal_investigator": { "id": 25201, "first_name": "FLORIAN", "last_name": "KRAMMER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "This contract supports the design and evaluation of innovative vaccine candidates and delivery platforms that aim to achieve durable, robust and broadly protective immunity. Activities may include immunologic analyses to inform vaccine design and identify surrogates/correlates of protection; in vitro and in vivo immunogenicity and efficacy testing; assay and reagent development; and clinical studies and trials. Additional studies are being conducted to evaluate the immune response to SARS-CoV-2 infection.", "keywords": [ "2019-nCoV", "Biological Assay", "COVID-19", "Clinical Research", "Clinical Trials", "Development", "Evaluation", "Immune response", "Immunity", "Immunologics", "In Vitro", "Reagent", "Research", "SARS-CoV-2 infection", "Support Contracts", "Vaccine Design", "Vaccines", "design", "efficacy testing", "immunogenicity", "in vivo", "innovation", "programs", "vaccine candidate", "vaccine delivery" ], "approved": true } }, { "type": "Grant", "id": "9511", "attributes": { "award_id": "75N93019C00052-P00002-9999-2", "title": "COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-10", "end_date": "2021-08-19", "award_amount": 969746, "principal_investigator": { "id": 25220, "first_name": "TED", "last_name": "ROSS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 888, "ror": "https://ror.org/00te3t702", "name": "University of Georgia", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 888, "ror": "https://ror.org/00te3t702", "name": "University of Georgia", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "The objective of this contract program is to support improvements in the immunogenicity and durability of seasonal influenza vaccines, SARS-COV-2 vaccines and the development of innovative influenza vaccine approaches that provide robust, durable, broadly protective mucosal and systemic anti-influenza immunity (“universal influenza vaccines”).", "keywords": [ "2019-nCoV", "Animal Model", "Animals", "Contractor", "Contracts", "Coronavirus", "Elderly", "Human", "Immune", "Immune response", "Immunity", "Individual", "Mucous Membrane", "National Institute of Allergy and Infectious Disease", "Obesity", "Recording of previous events", "United States National Institutes of Health", "Vaccinated", "Vaccines", "anti-influenza", "coronavirus disease", "design", "high risk", "high risk population", "immunogenicity", "influenza virus vaccine", "innovation", "next generation", "novel vaccines", "pregnant", "programs", "response", "seasonal influenza", "standard of care", "universal influenza vaccine", "universal vaccine", "vaccine development" ], "approved": true } }, { "type": "Grant", "id": "9512", "attributes": { "award_id": "75N93019C00052-P00002-9999-3", "title": "COVID supplement: A multi-site study seeking to study immune responses developed after infection with SARS-CoV-2", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-10", "end_date": "2021-08-19", "award_amount": 969655, "principal_investigator": { "id": 25220, "first_name": "TED", "last_name": "ROSS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 888, "ror": "https://ror.org/00te3t702", "name": "University of Georgia", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 888, "ror": "https://ror.org/00te3t702", "name": "University of Georgia", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "The Georgia University Research Foundation to support the National Cancer Institute's multi-site study seeking to determine if immune responses developed after confirmed infection with SARS-CoV-2.", "keywords": [ "2019-nCoV", "Foundations", "Immune response", "Infection", "National Cancer Institute", "Research", "Site", "Universities", "coronavirus disease" ], "approved": true } }, { "type": "Grant", "id": "9513", "attributes": { "award_id": "75N93019C00052-P00007-9999-3", "title": "COVID supplement: A multi-site study seeking to study immune responses developed after infection with SARS-CoV-2", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-10", "end_date": "2022-09-09", "award_amount": 1575867, "principal_investigator": { "id": 25220, "first_name": "TED", "last_name": "ROSS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 888, "ror": "https://ror.org/00te3t702", "name": "University of Georgia", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 888, "ror": "https://ror.org/00te3t702", "name": "University of Georgia", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "The Georgia University Research Foundation to support the National Cancer Institute's multi-site study seeking to determine if immune responses developed after confirmed infection with SARS-CoV-2.", "keywords": [ "2019-nCoV", "Foundations", "Immune response", "Infection", "National Cancer Institute", "Research", "Site", "Universities", "coronavirus disease" ], "approved": true } }, { "type": "Grant", "id": "9506", "attributes": { "award_id": "75N93019C00058-P00002-9999-2", "title": "Advanced Development of Medical Countermeasures for Infectious Diseases - COVID-19 Related Studies", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-09", "end_date": "2020-12-31", "award_amount": 51953, "principal_investigator": { "id": 25213, "first_name": "GEORGE", "last_name": "PAINTER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "To support the advanced development of a promising candidate therapeutic. The research and development activities to be supported will allow the candidate therapeutic product to progress along the product development pathway, and include preclinical and IND enabling development activities, and clinical safety and efficacy assessment.", "keywords": [ "2019-nCoV", "Advanced Development", "COVID-19", "Clinical", "Communicable Diseases", "Development", "Influenza Therapeutic", "Pathway interactions", "Safety", "medical countermeasure", "pre-clinical", "product development", "research and development", "therapeutic candidate" ], "approved": true } }, { "type": "Grant", "id": "9531", "attributes": { "award_id": "75N93019C00062-P00003-9999-2", "title": "COVID Supplement B Cell Epitope Discovery and Mechanisms of Antibody Protection.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-16", "end_date": "2022-03-15", "award_amount": 1810144, "principal_investigator": { "id": 25238, "first_name": "", "last_name": "", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "This contract supports the identification of human B cell epitopes derived from viral pathogens; such as Coronavirus, Dengue virus 4, Powassan virus, Chikungunya virus, and Venezuelan equine encephalitis virus, combined with basic studies to understand protective immunity mediated by antibodies, as well as pathological consequences of antibody responses.", "keywords": [ "Antibodies", "Antibody Response", "Antibody-mediated protection", "B-Lymphocyte Epitopes", "Chikungunya virus", "Coronavirus", "Dengue Virus", "Human", "Pathologic", "Powassan virus", "Support Contracts", "Venezuelan Equine Encephalitis Virus", "coronavirus disease", "pathogenic virus" ], "approved": true } }, { "type": "Grant", "id": "9517", "attributes": { "award_id": "75N93019C00065-P00002-9999-2", "title": "LARGE SCALE T CELL EPITOPE DISCOVERY - COVID Supplement", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-30", "end_date": "2020-09-29", "award_amount": 650336, "principal_investigator": { "id": 25225, "first_name": "ALESSANDRO", "last_name": "SETTE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 777, "ror": "", "name": "LA JOLLA INSTITUTE FOR IMMUNOLOGY", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 777, "ror": "", "name": "LA JOLLA INSTITUTE FOR IMMUNOLOGY", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The SARS-CoV-2 epitope Megapools (SARS-CoV-2 MPs) is used to study SARS-CoV-2 CD4 and CD8 specific T cell responses. The Megapool (MP) approach allows simultaneous testing of large number of epitopes. According to this approach large numbers of different epitopes are solubilized, pooled and re-lyophilized to avoid cell toxicity problems associated with high concentrations of DMSO typically encountered when single pre-solubilized epitopes are pooled. These MPs have been used for both CD4 and CD8 T cell epitope identification.", "keywords": [ "2019-nCoV", "CD8-Positive T-Lymphocytes", "CD8B1 gene", "Cells", "Contracts", "Coronavirus", "Dimethyl Sulfoxide", "Epitopes", "Freeze Drying", "Ships", "T cell response", "T-Lymphocyte Epitopes", "Testing", "Toxic effect", "coronavirus disease" ], "approved": true } }, { "type": "Grant", "id": "9527", "attributes": { "award_id": "75N93019C00065-P00006-9999-2", "title": "LARGE SCALE T CELL EPITOPE DISCOVERY - COVID Supplement", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-30", "end_date": "2021-09-29", "award_amount": 299928, "principal_investigator": { "id": 25233, "first_name": "STEPHEN", "last_name": "WILSON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 777, "ror": "", "name": "LA JOLLA INSTITUTE FOR IMMUNOLOGY", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 777, "ror": "", "name": "LA JOLLA INSTITUTE FOR IMMUNOLOGY", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The SARS-CoV-2 epitope Megapools (SARS-CoV-2 MPs) is used to study SARS-CoV-2 CD4 and CD8 specific T cell responses. The Megapool (MP) approach allows simultaneous testing of large number of epitopes. According to this approach large numbers of different epitopes are solubilized, pooled and re-lyophilized to avoid cell toxicity problems associated with high concentrations of DMSO typically encountered when single pre-solubilized epitopes are pooled. These MPs have been used for both CD4 and CD8 T cell epitope identification.", "keywords": [ "2019-nCoV", "CD8-Positive T-Lymphocytes", "CD8B1 gene", "Cells", "Contracts", "Coronavirus", "Dimethyl Sulfoxide", "Epitopes", "Freeze Drying", "Ships", "T cell response", "T-Lymphocyte Epitopes", "Testing", "Toxic effect", "coronavirus disease" ], "approved": true } } ], "meta": { "pagination": { "page": 1385, "pages": 1405, "count": 14046 } } }